An article co-written by UM Lead Dr Sarah Welsh and published in the New England Journal of Medicine has been described as a 'potential game changer'. The article, entitled 'Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease' shares the findings of a phase 2, open-label, single-group trial, which investigated the efficacy and safety of the HIF-2a inhibitor belzutifan (MK-6482, previously called PT2977), administered orally at a dose of 120 mg daily, in patients with renal cell carcinoma associated with VHL disease.
The article can be read here.